Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Donate
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
When Care(giving) Meet...
Live, educational event for the community around Greenville, SC.
/Events/MSF-Events/2019/One-Time-Events/When-Care(giving)-Meets-Love-(2)
Cooling Program
The Cooling Program offers a variety of items, free of charge, to help individuals with MS...
/Get-Help/MSF-Programs-Grants/Cooling-Program
Shop
Privacy
Terms of Use
Site Map
FDA approves Vumerity MS
October 31, 2019
Biogen and Alkermes announced U.S. Food and Drug Administration approved Vumerity™ (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. Biogen holds the exclusive, worldwide license to commercialize Vumerity and intends to make it available in the U.S. in the near future.
The FDA approval of Vumerity was based on a New Drug Application. It included data from studies comparing Vumerity and Tecfidera to establish bioequivalence, and partly relied on the FDA’s safety and efficacy findings for Tecfidera. Interim results from an EVOLVE-MS-1 study at the time of NDA submission included a low overall rate of patients who stopped using Vumerity because of adverse events, and a rate of less than 1 percent of patients who stopped using Vumerity because of adverse gastrointestinal events.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more
Study uncovers potential risks of common MS treatment
Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more